

AWARD NUMBER: W81XWH-16-1-0201

TITLE: Investigating Cooperation between KEAP1 and LKB1 Inactivation in Lung Adenocarcinoma

PRINCIPAL INVESTIGATOR: Landon Inge

CONTRACTING ORGANIZATION: St. Joseph's Hospital and Medical Center  
Phoenix, AZ 85013

REPORT DATE: August 2017

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b>					
1. REPORT DATE August 2017		2. REPORT TYPE Annual		3. DATES COVERED 08/01/2016 to 07/31/2017	
4. TITLE AND SUBTITLE  Investigating Cooperation between KEAP1 and LKB1 Inactivation in Lung Adenocarcinoma				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-16-1-0201	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S)  Landon J. Inge, PhD  E-Mail: landon.inge@dignityhealth.org				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  St. Joseph's Hospital and Medical Center Phoenix, AZ 85013				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)  U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT  Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Preliminary analysis in our laboratory reveals concurrent mutation of the LKB1 and KEAP1 tumor suppressors correlate with poor overall survival in lung adenocarcinoma (LA). Phenotypically, there is evidence to suggest that inactivation of KEAP1 may support adaptation to increased oxidative stress that results from LKB1 inactivation. We have found that inactivation of KEAP1 in the background of LKB1 inactivation results in increased growth and resistance to treatment. Further, we have evidence that cross-talk from the PERK kinase, may also further support adaptation to oxidative stress in combination with KEAP1 inactivation in LKB1-deficient LA. These findings suggest that KEAP1/LKB1 inactivation may represent a critical step in LA tumorigenesis and may have a role in therapeutic resistance. We are further exploring these findings using in vivo models.					
15. SUBJECT TERMS Lung adenocarcinoma, lung cancer, LKB1, STK11, KEAP1, therapeutic resistance.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT  Unclassified	18. NUMBER OF PAGES  15	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT  Unclassified	b. ABSTRACT  Unclassified	c. THIS PAGE  Unclassified			19b. TELEPHONE NUMBER (include area code)

## Table of Contents

	<u>Page</u>
1. Introduction.....	2
2. Keywords.....	3
3. Accomplishments.....	3
4. Impact/Future directions .....	5
5. Changes/Problems.....	6
6. Appendices.....	6

## 1.Introduction

Lung cancers contribute to more deaths globally than any other malignancy<sup>1</sup>. Lung cancers are a histologically diverse tumor type, classified into small and non-small cell subtypes, with non-small cell lung cancers accounting for over 70% of all lung cancers<sup>2</sup>. Non-small cell lung cancers are further sub-classified into squamous cell, adenocarcinoma, large cell and neuroendocrine. Lung adenocarcinoma (LA) has become predominate (~70% of cases)<sup>2</sup>, overtaking squamous cell carcinoma of the lung (SCC). The increase in LA has been attributed to several different factors, including changes in smoking behavior and environmental exposure. Genetic analyses indicate that LA and SCCs also differ considerably in regards to oncogenic mutations<sup>2</sup>. One of the most frequent mutations in LA are inactivating alterations to the *STK11/LKB1* gene<sup>3-5</sup>. Encoding a serine-threonine kinase, *LKB1* is a known tumor suppressor and *LKB1* inactivation is associated with poor overall survival in several different tumor types<sup>3</sup>. Deletion of the *Lkb1* gene simultaneously with expression of oncogenic KRAS (*KRAS*<sup>G12</sup>) in murine lung potentiates aggressive LA, characterized by rapid growth, short overall survival (8 weeks vs 24 weeks in KRAS only mice) and local and distant metastasis<sup>6</sup>. *LKB1* regulates several fundamental processes, including growth and metabolism<sup>3</sup>. While it is apparent that *LKB1* inactivation contributes greatly to tumorigenesis, loss of *LKB1* function also results in a variety of distinct metabolic changes, consistent with its' regulatory function in cellular metabolism<sup>3</sup>. Although these changes in cellular metabolism are thought to enable more aggressive growth, *LKB1* loss has been shown by both our group and others to result in increased oxidative stress (i.e. reactive oxygen species [ROS]) and *LKB1*-deficient LA cells are more sensitive to pharmacological agents that aggravate oxidative stress levels<sup>7,8</sup>. Parallel studies indicate that aggravation of oxidative stress due to limited nutrients and chronic hypoxia also induces cell death<sup>9</sup>. Further, *LKB1* inactivation cooperates with oncogenic *KRAS* mutation<sup>6</sup>, an alteration known to induce oxidative stress<sup>10</sup>. These conflicting effects (rapid growth vs increased cytotoxicity due to oxidative stress) resulting from *LKB1* inactivation highlight a potential requirement for additional genetic mutations in *LKB1*-deficient LA to overcome the negative effects of oxidative stress. The *NFE2L2* gene encodes for the Nrf2 transcription factor<sup>11,12</sup>. Nrf2 regulates a gene expression program involved in detoxification of ROS and xenobiotic compounds, enabling adaptation and resistance to oxidative stress. Unsurprisingly, Nrf2 also functions as a potent oncogene, enabling resistance to oxidative stress and thus promotion of carcinogenesis. Activity of Nrf2 is regulated through association with KEAP1. Under homeostatic conditions, Nrf2 is tightly bound to KEAP1, which sequesters Nrf2 for degradation via the proteosomal degradatory pathway. Increases in ROS levels enables disassociation of Nrf2 from KEAP1, allowing Nrf2 to translocate to the nucleus and activate gene transcription. Consistent with the pro-tumorigenic function of Nrf2, *KEAP1* functions as a tumor suppressor and inactivating mutations to *KEAP1* are found in several tumor types, including LA<sup>13</sup>. While it is apparent that much of the benefit of dysregulated NRF2-KEAP1 signaling is related to detoxification of ROS, there is also evidence that aberrant Nrf2 signaling also promotes adaptation of tumor associated metabolism<sup>14</sup>.

One of the conflicting paradigms regarding the contribution of *LKB1* to LA tumorigenesis has been how LA-deficient *LKB1* maintain growth and adapt to increased sensitivity to oxidative stress. Based upon the known functions of Nrf2 and KEAP1, we have hypothesized that inactivation of *KEAP1* in concert with *LKB1* inactivation may work cooperatively to promote and support tumorigenesis in LA. We have designed experiments to test this hypothesis and have evidence that inactivation of *KEAP1* promotes increased growth in *LKB1*-deficient LA and provides resistance to therapy.

## 2. Keywords

STK11, LKB1, KEAP1, Nrf2, oxidative stress, Lung adenocarcinoma, therapeutic resistance

## 3. Accomplishments

*Concurrent mutation of KEAP1 and LKB1 are common in lung adenocarcinoma and are associated with poor survival*

Analysis of LA carrying oncogenic mutations to *KRAS* revealed frequent co-mutation of *LKB1* and *KEAP1* in patient tumors and *LKB1*-deficient LA display a gene signature associated with Nrf2 gene transcription<sup>15</sup>. Based upon these observations, we analyzed the Cancer Genome Atlas LA dataset<sup>5</sup> for mutations to *KEAP1*, *LKB1* or co-mutations of *KEAP1* and *LKB1* and 5-year survival. Consistent with published data, co-occurrence of mutations to *KEAP1* and *LKB1* is highly significant ( $p < 0.001$ ). In analysis of COSMIC (Catalogue of Somatic Mutations in Cancer) cell line DNA sequencing data, concurrent mutation of *KEAP1* and *LKB1* in 14% of established LA cell lines (Table 1). More importantly, analysis of 5-year survival in LA patients from the TCGA dataset revealed reduced survival in LA patients with concurrent mutations to *KEAP1* and *LKB1* compared to LA patients harboring mutations to *LKB1* or *KEAP1* (Figure 1). Collectively, these data show that concurrent mutation of *LKB1* and *KEAP1* is common in LA and the presence of these mutations is associated with poor overall survival.

*Deletion of KEAP1 promotes growth of LA in vitro*

To test cooperativity between *LKB1* and *KEAP1* inactivation, we chose to utilize short-term cell cultures of murine LA cells collected from a well-characterized conditional transgenic model of LA. Developed by Jacks and colleagues, the *KRAS* mouse harbors an oncogenic *Kras* (*Kras*<sup>G12D</sup> or mtKras) gene flanked proximally by a floxed transcriptional stop sequence (lox-STOP-lox or LSL) knocked into the wild-type *Kras* gene locus<sup>16</sup>. Expression of oncogenic *Kras* is conditional, as the stop sequence in the LSL cassette prevents expression of oncogenic *Kras*. Transient expression of the Cre recombinase in the lung, via intranasal inhalation of a Cre adenovirus (adenoCre) results in DNA deletion of the LSL cassette and expression of mtKRAS. As mtKRAS expression is driven by its normal promoter, protein levels of mtKRAS are at normal physiological levels, unlike other approaches that utilize over-expression of mtKRAS via a viral promoter. mtKRAS mice display NSCLC pathogenesis comparable to human disease, with mtKRAS mice harboring early pre-neoplastic lesions (atypical adenomatous hyperplasia, epithelial hyperplasia, adenomas) 2 weeks post infection and high-grade NSCLC at later time points (~16 weeks post-infection). Adjusting the multiplicity of infection alters the number of lesions within the lung. Inclusion of floxed alleles of tumor suppressor genes (i.e. *Tp53*, *Lkb1*) via selective breeding allows for simultaneous deletion of tumor suppressors and activation of mtKras gene expression. Our laboratory currently maintains an active breeding colony of mtKras, mtKras/*tp53*<sup>fl/fl</sup> and mtKras/*Lkb1*<sup>fl/fl</sup> mice on a FVB/n background. mtKras/*LKB1*<sup>fl/fl</sup> mice (6-8 weeks old) were infected with adenoCre ( $1 \times 10^6$  pfu) via inhalation and monitored. 8 weeks post-infection, mice were sacrificed and tumor nodules dissected from the lungs. Tumor nodules were minced and suspended in media and tumor cells allowed to attach under standard cell culture conditions. After one week of growth, tumor cells were checked for fibroblast contamination. If present, fibroblasts were removed by incubating samples with 0.5% trypsin/EDTA for 1-2 minutes and rinsed with warm media. Samples were further trypsinized and expanded for experiments. We have found that these procedures produces cultures comprised entirely of *LKB1*-deficient LA tumor cells. Consistent with Cre-mediated deletion of *LKB1*, these cells lack *LKB1* (Figure 6) and still maintain expression of *KEAP1* and low levels of Nrf2 at normal cell culture conditions (Figures 2A, 6). To test the effects of *KEAP1* deletion in *LKB1*-deficient LA (*LKB1*-), we

utilized CRISPR (Clustered regularly interspaced short palindromic repeats) to specifically delete *KEAP1* in the DNA of our short-term murine cultures of mtKras/LKB1- LA cells. sgRNA sequences to murine *Keap1* using an online design tool (<http://crispr.mit.edu/>) that were cloned into the pLentiV2 CRISPR vector. Following puromycin selection, immunoblotting for Keap1 and Nrf2 in short-term cultures from mtKras/LKB1- tumor cells showed reduced Keap1, with a corresponding increase of Nrf2 (Figure 2A) in cells infected with sgRNA targeting Keap1. Infection with a non-targeting sgRNA had no effect. For comparison, we performed CRISPR mediated deletion of *Keap1* in a murine LA cell line wildtype for *Lkb1*, but carrying an oncogenic mutation to *Kras* and found t increased Nrf2, consistent with reduced KEAP1 expression (Figure 2A). We compared growth of LKB1- (3363D) and LKB1+ (CMT64) to test the effects of *Keap1* deletion on growth. As shown in figure 2B, deletion of *Keap1* in the 3363D (LKB1-) LA cells resulted in increased cell growth compared to 3363D cells infected with the non-targeting sgRNA. Surprisingly, CRISPR mediated deletion of *Keap1*, resulted in reduced growth in the LKB1-expressing CMT64 LA cells (Figure 2B). To confirm these observations, we chose to test the effects of KEAP1 expression in human LA lines. Consistent with LA patient tumors<sup>15</sup>, concurrent inactivation of *KEAP1* and *LKB1* are commonly present in established LA cell lines. We chose two lines, H2030 and A549, both shown to harbor inactivation mutations in *LKB1* and *KEAP1* (Table 1)<sup>13,17</sup> and stably re-expressed either KEAP1 or LKB1 using retroviral infection, followed by selection with puromycin. Notably, both H2030 and A549 also carrying oncogenic *KRAS*, but differ in regards to *TP53* status (H2030-*TP53*-; A549-*TP53*+)<sup>18</sup>. In addition, A549 harbor an activating mutation in *Nrf2*. Following puromycin selection, H2030 LA cells containing LKB1, KEAP1 or the empty vector (pBabe) were treated with the known LKB1 activators, phenformin and metformin. These agents indirectly activation LKB1 signaling by inhibiting mitochondrial complex I and LKB1 activity can be assayed by immunoblotting for phosphorylated AMPK (pAMPK), a downstream target of LKB1<sup>3</sup>. As expected, re-expression of LKB1 restored AMPK phosphorylation with phenformin and metformin treatment (figure 3A). Notably, neither drug induced pAMPK in H2030 cells re-expressing KEAP1 or pBabe. Re-expression of KEAP1 was found to reduce both Nrf2 and its downstream target HO-1 (Figure 3A), consistent with KEAP1's regulatory function. Interestingly, LKB1 re-expression increased Nrf2 expression in the H2030 cells (Figure 3A). We next compared the growth of H2030 and A549 LA cell lines re-expressing KEAP1, LKB1 or empty vector. As shown in Figure 3B, re-expression of KEAP1 reduced the growth of A549 and H2030 cells, compared to pBabe cells. LKB1 re-expression was found to also reduce the growth of H2030 LA cells, but had no effect upon A549 (Figure 3B).

#### *KEAP1 inactivation promotes resistance to chemotherapy*

We have recently shown that *LKB1* loss results in increased sensitivity to DNA damaging chemotherapy in LA<sup>19</sup>. Based upon the frequent concurrent mutation of *KEAP1* and *LKB1* in LA and Nrf2-mediated resistance to therapy<sup>20</sup>, we tested whether KEAP1 status had any role in these observations. As shown in Figure 4A, treatment with the DNA damaging agent, cisplatin, activated LKB1 signaling in A549 cells re-expressing LKB1 (A549-LKB1), but not A549 cells re-expressing KEAP1 (A549-KEAP1) or pBabe (A549-pBabe). A549-LKB1 cells also showed reduced DNA damage compared to A549-pBabe cells, as marked by the DNA damage marker  $\gamma$ H2AX, consistent with our previous work (Figure 4B). Surprisingly, A549-KEAP1 cells displayed considerably higher  $\gamma$ H2AX and cleaved Parp (a marker of apoptosis) relative to both A549-pBabe and A549-LKB1, suggesting that KEAP1 expression imparted increased sensitivity to cisplatin treatment. To test confirm these findings, H2030 and A549 cells re-expressing LKB1, KEAP1 or pBabe were treated with increasing doses of cisplatin and cell viability was determined after 48 hours of treatment. Consistent with the presence of increased DNA damage, A549-KEAP1 and H2030-KEAP1 cells displayed significantly

( $p < 0.005$ ) reduced viability in response to cisplatin compared to H2030 and A549 cells expressing LKB1 or pBabe (Figure 5A,B).

#### 4. Impact/Future directions

The primary hypothesis of this work was that concurrent mutation to *KEAP1* and *LKB1* cooperate to promote tumorigenesis and resistance to therapy. While our *in vitro* work still needs to be confirmed *in vivo* (see Changes/Problems), our collective data support this hypothesis. Using both chemo-naïve short term cultures of murine LA cells and established human LA cells, we have found that expression of *KEAP1* has a pronounced effect upon the growth of *LKB1*-deficient LA cells. It is notable that the effects of *KEAP1* in *LKB1*-deficient LA appear at manifest at higher cell numbers, suggesting that the effects of *KEAP1* upon the growth of *LKB1*-deficient LA may be related to metabolic alterations. As cells proliferate and become denser in culture, nutrients expectedly become more limited. Deletion of *KEAP1* is known to potentiate changes in cellular metabolism, specifically driving processes towards anabolic pathways that support proliferation<sup>14</sup> that are independent of ROS detoxification. Thus, it is quite possible that deletion of *KEAP1* and the subsequent shift towards anabolic metabolism may offset metabolic defects associated with *LKB1* inactivation unrelated to oxidative stress. We are currently designing experiments to test this possibility and are working with a longtime collaborator (Patrick Pirrotte) at the Translational Genomics Research Institute (Phoenix, AZ) to undertake MALDI based analysis of metabolites in our sg*KEAP1* murine LA cell lines. Current treatment of LA relies upon DNA damaging agents, specifically cisplatin and its analogues (carboplatin). We have found that loss of *LKB1* imparts sensitivity to DNA damaging treatment and more importantly found that a specific inhibitor to *wee1* kinase, a protein involved in DNA repair, synergized with cisplatin to markedly improve the survival of *mtKras/LKB1*-deficient NSCLC *in vivo*<sup>19</sup>. We found that *mtKras/LKB1*-deficient NSCLC tumors displayed defects in DNA repair<sup>19</sup>, however the exact mechanism/s behind this phenotype remained elusive. Our finding that *KEAP1* expression resulted in reduced survival and increased DNA damage from cisplatin, suggests that having an intact Nrf2-*KEAP1* regulatory pathway may play a critical role in mediating the effects of cisplatin and other DNA damaging treatments. Based upon our findings, we are currently testing whether *KEAP1* and Nrf2 are involved. This has substantial clinical impact, as the frequent incidence of concurrent *KEAP1/LKB1* inactivation in LA suggests that inhibition of Nrf2 may enable improved responses to DNA damaging treatments. Indeed, efforts are underway to develop Nrf2 inhibitors and we are investigating potential collaborations to test these compounds in our models.

We and others have shown increased activity of the Unfolded Protein Response (UPR) in *LKB1*-deficient LA<sup>8,15</sup>. The UPR functions as an adaptive stress for the Endoplasmic Reticulum (ER) and is activated by perturbations to protein synthesis within the ER<sup>21</sup>. Due to the highly oxidative environment of the ER, the UPR and specifically the UPR regulator, PERK also functions in detoxification of ROS<sup>22-24</sup>. Deletion of PERK results in increased ROS and more importantly, PERK can directly phosphorylate Nrf2, which disassociates Nrf2 from *KEAP1* and subsequently activating Nrf2 transcription<sup>22-24</sup>. We have previously found that *LKB1*-deficient LA display increased PERK signaling<sup>8</sup>. Recently, analysis of short term cultures of *mtKRAS/LKB1*-deficient LA cells has revealed that expression of PERK is highly upregulated (Figure 6). The increased expression of PERK, as well as our previous observations of increased PERK signaling may suggest that cross-talk between PERK and Nrf2 may be further supporting tumorigenesis of *LKB1/KEAP1*-deficient LA. This has become an additional area of focus for our laboratory and we are in process of applying for RO1 funding from NIH.

## 5. Changes/Problems

We proposed several parallel *in vivo* studies to support our *in vitro* experiments. These experiments were designed to take advantage of a publically available lentiviral Cas9/CRISPR construct that also includes a Cre recombinase cassette. This vector (pSECC) was designed to allow for cloning of user designed sgRNA and sgRNA, CAS9 and Cre expression *in vivo*<sup>25</sup>. The pSECC construct has been shown to successfully delete sgRNA targeted genes with simultaneous deletion of floxed DNA sequences<sup>25</sup>. Our proposed experiment was designed to target Keap1 in our mtKras/LKB1<sup>fl/fl</sup> transgenic model and downstream analysis of tumorigenesis. This approach would have been particularly valuable, as it would have been able to determine whether co-mutation of KEAP1 and LKB1 were involved in initiation of LA and also assess the effects of LKB1/KEAP1 co-mutation in the context of fully competent immune system. While we have successfully deleted *Keap1* *in vitro*, our attempts to apply the pSECC vector in our murine model has been problematic. Despite generating lentiviral particles at titers sufficient for *in vivo* infection ( $10^6$ - $10^8$ ), we have to date been unable to achieve both CAS9 deletion of Keap1 or Cre-mediated recombination of the LSL-mrKras and floxed LKB1 alleles in our mouse model. We have begun alternative experiments using short-term cultures of mtKras/LKB1- LA cell lines. These experiments (recently approved by the ACURO) will entail CAS9 deletion of KEAP1 *in vitro* followed by heterotopic implantation into immune-competent mice of the same background. These studies will enable validation of our *in vitro* studies and we have approval for a no-cost extension to complete this work.

## 6. Appendices

### a) Figure Legends:

**Figure 1:** Kaplan-Meier analysis of LA patient survival based on LKB1/STK11 and KEAP1 mutation from the TCGA dataset. Red-KEAP1 mutant patients, Blue-LKB1 mutant patients, Black-LKB1/KEAP1 co-mutant patients.

**Figure 2: A)** Immunoblot analysis of 3363D, 3381B (mtKras/LKB1-) and CMT64 (mtKras/LKB1+) murine cell lines following lentiviral infection with sgKEAP1 (sgKP1) or sgControl (sgCon) and selection in puromycin for one week. Total protein lysates were probed with antibodies specific to Nrf2, KEAP1 or Actin as a loading control. The human lung adenocarcinoma (*EGFR* mutant, *TP53* mutant) was used as a control for KEAP1 and Nrf2 expression. **B)** 50,000 cells (3363D, 3381B, CMT64) infected with the indicated sgRNAs were plated onto 6-well plates. Cells were trypsinized and counted on the indicated days using the Countess Cell Counter (Invitrogen).

**Figure 3: A)** Immunoblot analysis of H2030 (mtKRAS/LKB1-/TP53-) human LA cell lines after retroviral infection and puromycin selection. H2030 cells re-expressing KEAP1, LKB1 or empty vector (pBabe) were treated with vehicle (V), 2mM phenformin or 20mM metformin for 4 hours before lysis. Total protein lysates were probed with antibodies specific to Keap1, phosphorylated AMPK (pAMPK), AMPK, HO-1, Nrf2, LKB1 and Actin (as loading control). **B)** 50,000 A549 and H2030 LA cell lines stably expressing pBabe (blue), KEAP1 (red) or LKB1 (green) were plated and counted as described in Figure 1B.

**Figure 4: A)** A549-KEAP1, A549-LKB1 or A549-pBabe cells were treated with 4μM cisplatin for 6 hours before lysis. Total protein lysates were separated by SDS-PAGE and probed with antibodies specific to the indicated proteins. **B)** A549-KEAP1, A549-LKB1 or A549-pBabe cells



were treated with 4 $\mu$ M cisplatin for 48 hours before lysis. Total protein lysates were probed for  $\gamma$ H2AX (DNA damage) and cleaved Parp (clvd Parp, a marker of apoptosis). Actin was used as a loading control.

**Figure 5:** Cell viability of **(A)** A549-LKB1, A549-KEAP1, A549-pBabe and **(B)** H2030-LKB1, H2030-KEAP1 and H2030-pBabe treated with cisplatin at the indicated concentrations for 48 hours. Viability was determined using the CellTiterGlo™ kit (Invitrogen) according to manufacturer's instructions.

**Figure 6:** Immunoblot analysis of short term cultures of LA cells of tumor nodules collected from mtKras/Tp53- (395, 389) and mtKras/Lkb1- (3363D, 3381A, 7384) mice. Total protein lysates from cells established after two weeks in culture were probed using the indicated antibodies. Actin was used as a loading control.

Figure 1.





Figure 2

A



B




Figure 3




Figure 4




Figure 5





Figure 6



Sample Name	KEAP1 AA Mutation	STK11 AA Mutation
201T		p.L245F
ABC-1		
COR-L105		
EKVX		p.S216F
EMC-BAC-1		p.E165*, p.L164L
EMC-BAC-2		p.Q37*
H3255		
HCC-44	p.F211C	
HCC-78		
HCC-827		
HOP-62		
LC-2-ad		
LXF-289		
NCI-H1435	p.R413L	
NCI-H1563		p.Y272*,p.G242W
NCI-H1568		
NCI-H1573	p.A143P	p.S216F
NCI-H1651		
NCI-H1734		p.M51fs*14
NCI-H1755	p.E582*	p.P281fs*6
NCI-H1781		
NCI-H1793		
NCI-H1944	p.R272L	p.K78N, p.K62N
NCI-H1975		
NCI-H1993		p.E199*
NCI-H2023	p.W252C	
NCI-H2030	p.V568F	p.M392I, p.E357K, p.E317*, p.F157F
NCI-H2122	p.A170_R204del35	p.P281fs*6
NCI-H3122		
PC-14		
PC-3_[JPC-3]		
RERF-LC-KJ		
RERF-LC-MS	p.G119_M120>V	
SK-LU-1		
VMRC-LCD		

Table 1

## References

1. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. *CA: a cancer journal for clinicians* **64**, 9-29, doi:10.3322/caac.21208 (2014).
2. Richer, A. L., Friel, J. M., Carson, V. M., Inge, L. J. & Whitsett, T. G. Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR. *Pharmacogenomics and personalized medicine* **8**, 63-79, doi:10.2147/PGPM.S52845 (2015).
3. Shackelford, D. B. & Shaw, R. J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. *Nat Rev Cancer* **9**, 563-575, doi:10.1038/nrc2676 (2009).
4. Gill, R. K. *et al.* Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer. *Oncogene* **30**, 3784-3791, doi:10.1038/onc.2011.98 (2011).
5. Ding, L. *et al.* Somatic mutations affect key pathways in lung adenocarcinoma. *Nature* **455**, 1069-1075, doi:10.1038/nature07423 (2008).
6. Ji, H. *et al.* LKB1 modulates lung cancer differentiation and metastasis. *Nature* **448**, 807-810, doi:10.1038/nature06030 (2007).
7. Shackelford, D. *et al.* LKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug Phenformin. *Cancer cell* **23**, 143-158, doi:10.1016/j.ccr.2012.12.008 (2013).
8. Inge, L. J. *et al.* LKB1 inactivation sensitizes non-small cell lung cancer to pharmacological aggravation of ER stress. *Cancer letters* **352**, 187-195, doi:10.1016/j.canlet.2014.06.011 (2014).
9. Shaw, R. J. *et al.* The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. *Proc Natl Acad Sci USA* **101**, 3329-3335, doi:10.1073/pnas.0308061100 (2004).
10. Weinberg, F. *et al.* Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. *Proceedings of the National Academy of Sciences of the United States of America* **107**, 8788-8793, doi:10.1073/pnas.1003428107 (2010).
11. Mitsuishi, Y., Motohashi, H. & Yamamoto, M. The Keap1-Nrf2 system in cancers: stress response and anabolic metabolism. *Frontiers in oncology* **2**, 200, doi:10.3389/fonc.2012.00200 (2012).
12. Jaramillo, M. C. & Zhang, D. D. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. *Genes Dev* **27**, 2179-2191, doi:10.1101/gad.225680.113 (2013).
13. Singh, A. *et al.* Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. *PLoS medicine* **3**, e420, doi:10.1371/journal.pmed.0030420 (2006).
14. Mitsuishi, Y. *et al.* Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. *Cancer cell* **22**, 66-79, doi:10.1016/j.ccr.2012.05.016 (2012).
15. Skoulidis, F. *et al.* Co-occurring genomic alterations define major subsets of KRAS - mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. *Cancer discovery*, doi:10.1158/2159-8290.CD-14-1236 (2015).
16. Jackson, E. L. *et al.* Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. *Genes Dev* **15**, 3243-3248, doi:10.1101/gad.943001 (2001).
17. Sanchez-Cespedes, M. *et al.* Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. *Cancer Research* **62**, 3659-3662 (2002).
18. Matsumoto, S. *et al.* Prevalence and specificity of LKB1 genetic alterations in lung cancers. *Oncogene* **26**, 5911-5918, doi:10.1038/sj.onc.1210418 (2007).

19. Richer, A. L. *et al.* WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer. *Cancer Res*, doi:10.1158/0008-5472.CAN-16-3565 (2017).
20. Tao, S. *et al.* Oncogenic KRAS confers chemoresistance by upregulating NRF2. *Cancer Res* **74**, 7430-7441, doi:10.1158/0008-5472.CAN-14-1439 (2014).
21. Ron, D., Ron, D., Walter, P. & Walter, P. Signal integration in the endoplasmic reticulum unfolded protein response. *Nat. Rev. Mol. Cell Biol.* **8**, 519, doi:doi:10.1038/nrm2199 (2007).
22. Cullinan, S. B. & Diehl, J. A. PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress. *J Biol Chem* **279**, 20108-20117, doi:10.1074/jbc.M314219200 (2004).
23. Cullinan, S. B. & Diehl, J. A. Coordination of ER and oxidative stress signaling: the PERK/Nrf2 signaling pathway. *The international journal of biochemistry & cell biology* **38**, 317-332, doi:10.1016/j.biocel.2005.09.018 (2006).
24. Cullinan, S. B. *et al.* Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. *Molecular and cellular biology* **23**, 7198-7209 (2003).
25. Sanchez-Rivera, F. J. *et al.* Rapid modelling of cooperating genetic events in cancer through somatic genome editing. *Nature* **516**, 428-431, doi:10.1038/nature13906 (2014).